Cargando…
Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
Despite advances in treatments and improved survival, patients with pulmonary hypertension still experience poor exercise and functional capacity, which has a significant detrimental impact on their quality of life. The nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine 3′,5′-monopho...
Autores principales: | Lian, Tian-Yu, Jiang, Xin, Jing, Zhi-Cheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402909/ https://www.ncbi.nlm.nih.gov/pubmed/28458514 http://dx.doi.org/10.2147/DDDT.S117277 |
Ejemplares similares
-
First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension
por: Spreemann, Till, et al.
Publicado: (2017) -
The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012) -
Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension
por: Murata, Mitsushige, et al.
Publicado: (2017) -
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011) -
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
por: Frey, Reiner, et al.
Publicado: (2013)